DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.
This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

(A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and

(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Patrick N. Breysse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

Christopher M. Reh, Ph.D.
Associate Director
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention
*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to “...effectuate and implement the health related authorities” of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to “...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.
## VERSION HISTORY

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>August 2021</td>
<td>Final toxicological profile released</td>
</tr>
<tr>
<td>May 2019</td>
<td>Draft for public comment toxicological profile released</td>
</tr>
<tr>
<td>March 2011</td>
<td>Addendum to the toxicological profile released</td>
</tr>
<tr>
<td>August 1995</td>
<td>Final toxicological profile released</td>
</tr>
</tbody>
</table>
CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Jennifer Przybyla, Ph.D.  
Heather Carlson-Lynch, M.S., D.A.B.T.
Julie M. Klotzbach, Ph.D.
Jenny S. Crisman, B.S.

ATSDR, Office of Innovation and Analytics,  
Toxicology Section, Atlanta, GA  
SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:  
Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for  
Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National  
Toxicology Program (NTP).

Additional reviews for science and/or policy:  
ATSDR, Office of Community Health and Hazard Assessment; ATSDR, Office of Capacity  
Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of  
Laboratory Science; NCEH, Division of Environmental Health Science and Practice.

PEER REVIEWERS

1. Martin D. Brand, Ph.D., Buck Institute for Research on Aging (previous affiliation: University of  
   Cambridge), Novato, California
2. David Janz, Ph.D., Department of Veterinary Biomedical Sciences, Western College of  
   Veterinary Medicine, Saskatoon, Saskatchewan, Canada
3. David M. Wood, MD, FBPhS, Medical Toxicology Office, Guy’s Hospital, London, United  
   Kingdom

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers  
were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response,  
Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers’ comments and determine whether changes will be made to the  
profile based on comments. The peer reviewers’ comments and responses to these comments are part of  
the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final  
content. The responsibility for the content of this profile lies with ATSDR.
## CONTENTS

DISCLAIMER ........................................................................................................................................ ii
FOREWORD .......................................................................................................................................... iii
VERSION HISTORY ........................................................................................................................... iii
CONTRIBUTORS & REVIEWERS .......................................................................................................... vi
CONTENTS .......................................................................................................................................... vii
LIST OF FIGURES ................................................................................................................................ ix
LIST OF TABLES ................................................................................................................................. x

CHAPTER 1. RELEVANCE TO PUBLIC HEALTH ................................................................................ 1
  1.1 OVERVIEW AND U.S. EXPOSURES .......................................................................................... 1
  1.2 SUMMARY OF HEALTH EFFECTS ........................................................................................... 2
  1.3 MINIMAL RISK LEVELS (MRLs) ............................................................................................. 6

CHAPTER 2. HEALTH EFFECTS ....................................................................................................... 9
  2.1 INTRODUCTION .......................................................................................................................... 9
  2.2 DEATH ...................................................................................................................................... 43
  2.3 BODY WEIGHT ............................................................................................................................ 51
  2.4 RESPIRATORY ........................................................................................................................... 54
  2.5 CARDIOVASCULAR ................................................................................................................... 55
  2.6 GASTROINTESTINAL ................................................................................................................ 57
  2.7 HEMATOLOGICAL ...................................................................................................................... 59
  2.8 MUSCULOSKELETAL ................................................................................................................ 61
  2.9 HEPATIC .................................................................................................................................. 62
  2.10 RENAL .................................................................................................................................... 65
  2.11 DERMAL .................................................................................................................................. 68
  2.12 OCULAR .................................................................................................................................. 69
  2.13 ENDOCRINE ............................................................................................................................ 73
  2.14 IMMUNOLOGICAL .................................................................................................................... 74
  2.15 NEUROLOGICAL ...................................................................................................................... 76
  2.16 REPRODUCTIVE ..................................................................................................................... 78
  2.17 DEVELOPMENTAL ................................................................................................................... 79
  2.18 OTHER NONCANCER .............................................................................................................. 80
    2.18.1 Metabolic Effects from Uncoupling of Oxidative Phosphorylation ................................ 80
    2.18.2 Mechanism of Action—Oxidative Phosphorylation Uncoupling ................................... 84
    2.18.3 Effects on Hearing ........................................................................................................... 87
  2.19 CANCER ................................................................................................................................. 87
  2.20 GENOTOXICITY ....................................................................................................................... 88

CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL
  INTERACTIONS ................................................................................................................................. 98
  3.1 TOXICOKINETICS ..................................................................................................................... 98
    3.1.1 Absorption .......................................................................................................................... 98
    3.1.2 Distribution .......................................................................................................................... 99
    3.1.3 Metabolism ........................................................................................................................ 101
    3.1.4 Excretion ............................................................................................................................ 105
    3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models ........ 107
    3.1.6 Animal-to-Human Extrapolations ...................................................................................... 107
# Chapter 6. Adequacy of the Database

## 6.1 Information on Health Effects

## 6.2 Identification of Data Needs

## 6.3 Ongoing Studies

# Chapter 7. Regulations and Guidelines

# Chapter 8. References

## Appendices

- **Appendix A.** ATSDR Minimal Risk Levels and Worksheets
- **Appendix B.** Literature Search Framework for Dinitrophenols
- **Appendix C.** User’s Guide
- **Appendix D.** Quick Reference for Health Care Providers
- **Appendix E.** Glossary
- **Appendix F.** Acronyms, Abbreviations, and Symbols
LIST OF FIGURES

1-1. Health Effects Found in Humans and Animals Following Oral Exposure to 2,4-Dinitrophenol ........ 3
1-2. Summary of Sensitive Targets of 2,4-Dinitrophenol – Oral ................................................................. 7
2-1. Overview of the Number of Studies Examining 2,4-Dinitrophenol Health Effects ...................... 12
2-2. Levels of Significant Exposure to 2,4-Dinitrophenol – Oral .............................................................. 35
3-1. Nitro Reduction of 2,4-Dinitrophenol .............................................................................................. 103
5-1. Number of NPL Sites with Dinitrophenol Contamination .............................................................. 121
6-1. Summary of Existing Health Effects Studies on 2,4-Dinitrophenol By Route and Endpoint .......... 140
LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for 2,4-Dinitrophenol ................................................................. 8
2-1. Levels of Significant Exposure to 2,4-Dinitrophenol – Oral .................................................... 13
2-2. Levels of Significant Exposure to 2,4-Dinitrophenol – Dermal .............................................. 42
2-3. Case Reports of Human Fatalities After Oral Exposure to 2,4-Dinitrophenol ......................... 44
2-4. Mortality in Laboratory Animals Given a Single Gavage Dose of 2,4-Dinitrophenol ............... 47
2-5. Temperature Dependence of Intraperitoneal LD₅₀ Values in Mice ........................................ 51
2-6. Genotoxicity of 2,4-Dinitrophenol In Vivo ............................................................................. 89
2-7. Genotoxicity of Dinitrophenols In Vitro .................................................................................. 89
2-8. Genotoxicity of Dinitrophenol Metabolites In Vivo .............................................................. 94
2-9. Genotoxicity of Dinitrophenol Metabolites In Vitro .............................................................. 95
4-1. Chemical Identity of Isomers of Dinitrophenols .................................................................... 117
4-2. Physical and Chemical Properties of Dinitrophenols ............................................................ 118
5-1. Facilities that Produce, Process, or Use 2,4-Dinitrophenol ..................................................... 123
5-2. Releases to the Environment from Facilities that Produce, Process, or Use 2,4-Dinitrophenol .. 126
5-3. Lowest Limit of Detection Based on Standards ................................................................. 134
5-4. 2,4-Dinitrophenol Levels in Water, Soil, and Air of National Priorities List (NPL) Sites .......... 135
7-1. Regulations and Guidelines Applicable to Dinitrophenols ..................................................... 147